R Pieters

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. ncbi request reprint Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia
    Wendy A G Stams
    Erasmus Medical Ceneter University Medical Center Rotterdam Sophia Children s Hospital, Division of Pediatric Oncology Hematology, Dr Molewaterplein 60, 3015 GJ Rotterdam, The Netherlands
    Blood 105:4223-5. 2005
  2. ncbi request reprint Molecular pharmacodynamics in childhood leukemia
    R Pieters
    University Medical Center Rotterdam, Sophia Childrens Hospital, Pediatric Oncology Hematology, Rotterdam, The Netherlands
    Int J Hematol 78:402-13. 2003
  3. doi request reprint Biology and treatment of acute lymphoblastic leukemia
    Rob Pieters
    Department of Pediatric Oncology and Hematology, Erasmus MC Sophia Children s Hospital, Dr Molewaterplein 60, Rotterdam, The Netherlands
    Hematol Oncol Clin North Am 24:1-18. 2010
  4. ncbi request reprint [Acute lymphoblastic leukaemia in children and adolescents: chance of cure now higher than 80%]
    Rob Pieters
    Erasmus MC Sophia Kinderziekenhuis, afd Kinderoncologie hematologie, The Netherlands
    Ned Tijdschr Geneeskd 154:A1577. 2010
  5. pmc L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase
    Rob Pieters
    Erasmus MC Sophia Children s Hospital, Rotterdam, Netherlands
    Cancer 117:238-49. 2011
  6. doi request reprint Infant acute lymphoblastic leukemia: Lessons learned and future directions
    Rob Pieters
    Erasmus MC Sophia Children s Hospital, Dr Molewaterplein 60, 3015GJ, Rotterdam, The Netherlands
    Curr Hematol Malig Rep 4:167-74. 2009
  7. ncbi request reprint A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial
    Rob Pieters
    Dutch Childhood Oncology Group DCOG, Netherlands Erasmus MC Sophia Children s Hospital, Rotterdam, Netherlands
    Lancet 370:240-50. 2007
  8. ncbi request reprint Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trial
    Rob Pieters
    Department of Pediatric Oncology and Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Blood 112:4832-8. 2008
  9. doi request reprint Biology and treatment of acute lymphoblastic leukemia
    Rob Pieters
    Department of Pediatric Oncology and Hematology, Erasmus MC Sophia Children s Hospital, Dr Molewaterplein 60, Rotterdam, The Netherlands
    Pediatr Clin North Am 55:1-20, ix. 2008
  10. ncbi request reprint Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences
    M van Grotel
    Department of Pediatric Oncology Hematology, Erasmus University Medical Center Sophia Children s Hospital, Rotterdam, The Netherlands
    Leukemia 22:124-31. 2008

Detail Information

Publications143 found, 100 shown here

  1. ncbi request reprint Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia
    Wendy A G Stams
    Erasmus Medical Ceneter University Medical Center Rotterdam Sophia Children s Hospital, Division of Pediatric Oncology Hematology, Dr Molewaterplein 60, 3015 GJ Rotterdam, The Netherlands
    Blood 105:4223-5. 2005
    ..009). We conclude that resistance to l-asparaginase and relapse risk are associated with high expression of AS in TEL-AML1-negative but not TEL-AML1-positive B-lineage ALL...
  2. ncbi request reprint Molecular pharmacodynamics in childhood leukemia
    R Pieters
    University Medical Center Rotterdam, Sophia Childrens Hospital, Pediatric Oncology Hematology, Rotterdam, The Netherlands
    Int J Hematol 78:402-13. 2003
  3. doi request reprint Biology and treatment of acute lymphoblastic leukemia
    Rob Pieters
    Department of Pediatric Oncology and Hematology, Erasmus MC Sophia Children s Hospital, Dr Molewaterplein 60, Rotterdam, The Netherlands
    Hematol Oncol Clin North Am 24:1-18. 2010
    ..This article discusses the factors used in risk stratification and the treatment of pediatric ALL...
  4. ncbi request reprint [Acute lymphoblastic leukaemia in children and adolescents: chance of cure now higher than 80%]
    Rob Pieters
    Erasmus MC Sophia Kinderziekenhuis, afd Kinderoncologie hematologie, The Netherlands
    Ned Tijdschr Geneeskd 154:A1577. 2010
    ..It is anticipated that genomic research will lead to better classification and to more personalized therapy for individual patients...
  5. pmc L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase
    Rob Pieters
    Erasmus MC Sophia Children s Hospital, Rotterdam, Netherlands
    Cancer 117:238-49. 2011
    ..This article provides an overview of available evidence for optimal use of Erwinia asparaginase in the treatment of ALL...
  6. doi request reprint Infant acute lymphoblastic leukemia: Lessons learned and future directions
    Rob Pieters
    Erasmus MC Sophia Children s Hospital, Dr Molewaterplein 60, 3015GJ, Rotterdam, The Netherlands
    Curr Hematol Malig Rep 4:167-74. 2009
    ..New genetic and epigenetic insights into the biology of MLL-rearranged ALL suggest new possibilities for therapies...
  7. ncbi request reprint A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial
    Rob Pieters
    Dutch Childhood Oncology Group DCOG, Netherlands Erasmus MC Sophia Children s Hospital, Rotterdam, Netherlands
    Lancet 370:240-50. 2007
    ..We also did a randomised trial to establish the value of a late intensification course...
  8. ncbi request reprint Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trial
    Rob Pieters
    Department of Pediatric Oncology and Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Blood 112:4832-8. 2008
    ..This trial was registered at http://www.controlled-trials.com as no. ISRCTN 75734403...
  9. doi request reprint Biology and treatment of acute lymphoblastic leukemia
    Rob Pieters
    Department of Pediatric Oncology and Hematology, Erasmus MC Sophia Children s Hospital, Dr Molewaterplein 60, Rotterdam, The Netherlands
    Pediatr Clin North Am 55:1-20, ix. 2008
    ..This article discusses the factors used in risk stratification and the treatment of pediatric ALL...
  10. ncbi request reprint Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences
    M van Grotel
    Department of Pediatric Oncology Hematology, Erasmus University Medical Center Sophia Children s Hospital, Rotterdam, The Netherlands
    Leukemia 22:124-31. 2008
    ..Most cases with lower TAL1 levels were HOX11L2 or CALM-AF10 positive. NOTCH1 mutations did not predict for outcome. Classification into T-cell developmental subgroups was not predictive for outcome...
  11. doi request reprint EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia
    B V Balgobind
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Leukemia 24:942-9. 2010
    ..Further research should explain the role of EVI1+ in disease biology in these cases. Remarkably, no 3q26 abnormalities were identified in EVI1+ pediatric AML...
  12. ncbi request reprint Multidrug resistance genes in infant acute lymphoblastic leukemia: Ara-C is not a substrate for the breast cancer resistance protein
    R W Stam
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Leukemia 18:78-83. 2004
    ..8/T6400, also did not modulate Ara-C cytotoxicity. Therefore, we conclude that Ara-C is not a substrate for BCRP and that MDR proteins do not play a significant role in drug resistance in infant ALL...
  13. doi request reprint Final height and IGF1 in adult survivors of Wilms tumour
    K Blijdorp
    Department of Paediatric Oncology Haematology, Erasmus Medical Center Sophia Children s Hospital, Rotterdam, PO Box 2060, 3000 CB Rotterdam, The Netherlands
    Eur J Endocrinol 169:445-51. 2013
    ..The aim was to evaluate final height and IGF1 levels in nephrectomized Wilms tumour survivors when compared with healthy Dutch references and survivors of other cancer types...
  14. doi request reprint Hypermethylation of specific microRNA genes in MLL-rearranged infant acute lymphoblastic leukemia: major matters at a micro scale
    D J P M Stumpel
    Department of Pediatric Oncology Hematology, Erasmus Medical Center, Sophia Children s Hospital, Rotterdam, The Netherlands
    Leukemia 25:429-39. 2011
    ..In this study, we provide additional evidence that they should be tested for their efficacy in MLL-rearranged infant ALL in in vivo models...
  15. ncbi request reprint mRNA expression levels of (co)chaperone molecules of the glucocorticoid receptor are not involved in glucocorticoid resistance in pediatric ALL
    W J E Tissing
    Division of Pediatric Oncology Hematology, Erasmus MC Sophia Childrens Hospital, University Medical Center Rotterdam, The Netherlands
    Leukemia 19:727-33. 2005
    ..GC resistance in childhood ALL cannot be attributed to different mRNA expression levels of the investigated (co)chaperone molecules involved in GC binding and transport to the nucleus...
  16. doi request reprint Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol
    V H J van der Velden
    Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Leukemia 23:1073-9. 2009
    ..These data indicate that MRD diagnostics has added value for recognition of risk groups in infant ALL and that MRD diagnostics can be used for treatment intervention in infant ALL as well...
  17. ncbi request reprint Differential expression of p73 isoforms in relation to drug resistance in childhood T-lineage acute lymphoblastic leukaemia
    M Meier
    Department of Paediatric Oncology Haematology, Erasmus MC Sophia Children s Hospital, Erasmus University Medical Centre, Rotterdam, The Netherlands
    Leukemia 20:1377-84. 2006
    ..Our results suggest that childhood T-ALL is associated with a high expression of DeltaTA-p73. These isoforms may play a role in cellular resistance to DNA-damaging drugs in children at initial diagnosis of T-ALL...
  18. ncbi request reprint Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia
    Wendy A G Stams
    Division of Pediatric Oncology Hematology, Erasmus MC, Sophia Children s Hospital, Rotterdam, Netherlands
    Clin Cancer Res 11:2974-80. 2005
    ....
  19. doi request reprint Endocrine late sequelae in long-term survivors of childhood non-Hodgkin lymphoma
    M van Waas
    Department of Pediatric Oncology Hematology, Erasmus Medical Center, Rotterdam, The Netherlands
    Ann Oncol 23:1626-32. 2012
    ..Aim of this study was to investigate the long-term endocrine effects of treatment of childhood non-Hodgkin lymphoma (NHL)...
  20. doi request reprint Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia
    A Hartman
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, PO Box 2060, 3000 CB Rotterdam, The Netherlands
    Leuk Res 34:154-9. 2010
    ..Impaired motor performance in children who completed treatment for acute lymphoblastic leukemia (ALL) may be related to polymorphisms of the metabolising gene CYP3A5 or vincristine toxicity related genes MDR-1 and MAPT...
  21. doi request reprint NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols
    L Zuurbier
    Department of Pediatric Oncology Hematology, Sophia Children s Hospital, Erasmus University Medical Center, Rotterdam, The Netherlands
    Leukemia 24:2014-22. 2010
    ..Comparing our data with other studies, we conclude that the prognostic significance for NOTCH1/FBXW7 mutations is not consistent and may depend on the treatment protocol given...
  22. ncbi request reprint MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia
    M M van den Heuvel-Eibrink
    Department of Hematology, University Hospital, Rotterdam, The Netherlands
    Blood 97:3605-11. 2001
    ..Blood. 2001;97:3605-3611)..
  23. ncbi request reprint Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment
    Amy Holleman
    Division of Pediatric Oncology Hematology, Erasmus University Medical Center, Sophia Children s Hospital, Rotterdam, The Netherlands
    N Engl J Med 351:533-42. 2004
    ..Childhood acute lymphoblastic leukemia (ALL) is curable with chemotherapy in approximately 80 percent of patients. However, the cause of treatment failure in the remaining 20 percent of patients is largely unknown...
  24. ncbi request reprint Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells
    Esther Hulleman
    Department of Pediatric Oncology and Hematology, Erasmus Medical Center Sophia Children s Hospital, University Medical Center, Rotterdam, The Netherlands
    Blood 113:2014-21. 2009
    ..Together, these findings indicate the importance of the glycolytic pathway in glucocorticoid resistance in ALL and suggest that targeting glycolysis is a viable strategy for modulating prednisolone resistance in ALL...
  25. doi request reprint Decreased ovarian function is associated with obesity in very long-term female survivors of childhood cancer
    W van Dorp
    Department of Paediatric Oncology Haematology, Erasmus MC Sophia Children s Hospital, Dr Molewaterplein 60, 3015 GJ, Rotterdam, The Netherlands
    Eur J Endocrinol 168:905-12. 2013
    ..In the general population, obesity has a negative influence on female fertility. We aimed to evaluate whether obesity and serum insulin are associated with decreased ovarian reserve markers in CCS...
  26. ncbi request reprint Relation between genetic variants of the ataxia telangiectasia-mutated (ATM) gene, drug resistance, clinical outcome and predisposition to childhood T-lineage acute lymphoblastic leukaemia
    M Meier
    Department of Paediatric Oncology Haematology, Erasmus MC Sophia Children s Hospital, Erasmus University Medical Centre, Rotterdam, The Netherlands
    Leukemia 19:1887-95. 2005
    ..05). The association between five coding ATM alterations in T-ALL, their germline presence, white blood cell count and unfavourable outcome may point to a role for ATM in the development of T-ALL in these children...
  27. ncbi request reprint Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia
    R W Stam
    Erasmus MC Sophia Children s Hospital, Department of Pediatric Oncology Hematology, Rotterdam, The Netherlands
    Leukemia 20:264-71. 2006
    ..These observations imply that suppression of FHIT may be required for the development of MLL, and provide new insights into leukemogenesis and therapeutic possibilities for MLL...
  28. doi request reprint High BRE expression in pediatric MLL-rearranged AML is associated with favorable outcome
    B V Balgobind
    Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Leukemia 24:2048-55. 2010
    ..Although further investigation for the role of BRE in leukemogenesis and outcome is warranted, high BRE expression is an independent prognostic factor for pRFS in pediatric AML...
  29. ncbi request reprint MDR1 expression in poor-risk acute myeloid leukemia with partial or complete monosomy 7
    M M van den Heuvel-Eibrink
    Department of Hematology, University Hospital and Erasmus University, Rotterdam, The Netherlands
    Leukemia 15:398-405. 2001
    ..We conclude that MDR1 expression in -7/7q- AML patients is upregulated at transcriptional, but not at translational level, suggesting that mechanisms other than MDR1 are responsible for the poor prognosis in these patients...
  30. doi request reprint Cooperative genetic defects in TLX3 rearranged pediatric T-ALL
    P van Vlierberghe
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Leukemia 22:762-70. 2008
    ..This study provides a genome-wide overview of copy number changes in TLX3 rearranged T-ALL and offers great new challenges for the identification of new target genes that may play a role in the pathogenesis of T-ALL...
  31. doi request reprint Components of the metabolic syndrome in 500 adult long-term survivors of childhood cancer
    M van Waas
    Department of Paediatric Oncology Haematology, Erasmus Medical Centre, Sophia Children s Hospital, Rotterdam, The Netherlands
    Ann Oncol 21:1121-6. 2010
    ..A cluster of abnormalities that contribute to the metabolic syndrome may be expressed at a higher level and therefore result in an increased risk for diabetes mellitus and cardiovascular diseases...
  32. ncbi request reprint A new recurrent 9q34 duplication in pediatric T-cell acute lymphoblastic leukemia
    P van Vlierberghe
    Erasmus MC Sophia Children s Hospital, Department of Pediatric Oncology Hematology, Rotterdam, The Netherlands
    Leukemia 20:1245-53. 2006
    ..We showed that both of these genetic abnormalities occur independently from this newly identified 9q34 duplication...
  33. doi request reprint Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options
    Dominique J P M Stumpel
    Department of Pediatric Oncology Hematology, Erasmus Medical Center Sophia Children s Hospital, Rotterdam, The Netherlands
    Blood 114:5490-8. 2009
    ..Therefore, inhibition of aberrant DNA methylation may be an important novel therapeutic strategy for MLL-rearranged ALL in infants...
  34. ncbi request reprint Chemical genomic screening identifies LY294002 as a modulator of glucocorticoid resistance in MLL-rearranged infant ALL
    J A P Spijkers-Hagelstein
    Department of Pediatric Oncology Hematology, Erasmus Medical Center Sophia Children s Hospital, Rotterdam, The Netherlands
    Leukemia 28:761-9. 2014
    ..Thus, implementing FDA-approved PI3K inhibitors in current treatments may potentially improve the GC response and prognosis in patients with MLL-rearranged ALL. ..
  35. doi request reprint Src kinase-induced phosphorylation of annexin A2 mediates glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia
    J A P Spijkers-Hagelstein
    Department of Pediatric Oncology Haematology, Erasmus Medical Center Sophia Children s Hospital, Dr Molewaterplein 50, Rotterdam, The Netherlands
    Leukemia 27:1063-71. 2013
    ....
  36. doi request reprint Germline variation in the MTHFR and MTRR genes determines the nadir of bone density in pediatric acute lymphoblastic leukemia: a prospective study
    M L te Winkel
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Bone 48:571-7. 2011
    ..This study aims to identify folate-metabolism-related genetic risk factors for low bone mineral density (BMD) during/after pediatric acute lymphoblastic leukemia (ALL) treatment...
  37. pmc Differential expression and prognostic significance of SOX genes in pediatric medulloblastoma and ependymoma identified by microarray analysis
    Judith M de Bont
    Department of Pediatric Oncology and Hematology, Erasmus MC Sophia Children s Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Neuro Oncol 10:648-60. 2008
    ....
  38. ncbi request reprint Altered expression of miR-24, miR-126 and miR-365 does not affect viability of childhood TCF3-rearranged leukemia cells
    F Akbari Moqadam
    Department of Pediatric Oncology and Hematology, Erasmus MC Sophia Children s Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Leukemia 28:1008-14. 2014
    ....
  39. doi request reprint MiR-125b, miR-100 and miR-99a co-regulate vincristine resistance in childhood acute lymphoblastic leukemia
    F Akbari Moqadam
    Department of Pediatric Oncology and Hematology, Erasmus MC Sophia Children s Hospital, University Medical Centre Rotterdam, Rotterdam, The Netherlands
    Leuk Res 37:1315-21. 2013
    ..05). The concerted function of miR-125b in combination with miR-99a and/or miR-100 illustrates the complexity of vincristine-resistant pediatric ALL...
  40. doi request reprint Genetic variation may modify ovarian reserve in female childhood cancer survivors
    W van Dorp
    Department of Paediatric Oncology Haematology, ErasmusMC University Medical Centre Sophia s Children s Hospital Rotterdam, Dr Molewaterplein 60, 3015 GJ Rotterdam, The Netherlands
    Hum Reprod 28:1069-76. 2013
    ..Are genetic polymorphisms, previously identified as being associated with age at menopause in the healthy population, associated with ovarian reserve and predicted age at menopause in adult long-term survivors of childhood cancer?..
  41. pmc Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target
    S A Hartsink-Segers
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Leukemia 27:560-8. 2013
    ....
  42. doi request reprint Frequency of WT1 and 11p15 constitutional aberrations and phenotypic correlation in childhood Wilms tumour patients
    H Segers
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Eur J Cancer 48:3249-56. 2012
    ..Therefore, we investigated the frequency of constitutional aberrations in combination with phenotype...
  43. doi request reprint Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia
    D J P M Stumpel
    Department of Pediatric Oncology Hematology, Erasmus Medical Center, Sophia Children s Hospital, Rotterdam, The Netherlands
    Leukemia 26:682-92. 2012
    ..Given the presented potential of HDAC inhibitors to target important proto-oncogenes including the leukemia-specific MLL fusion in vitro, these agents should urgently be tested in in vivo models and subsequent clinical trials...
  44. doi request reprint Discovery of new microRNAs by small RNAome deep sequencing in childhood acute lymphoblastic leukemia
    D Schotte
    Department of Pediatric Oncology and Hematology, Erasmus MC Sophia Children s Hospital, Erasmus University Medical Center, Rotterdam, The Netherlands
    Leukemia 25:1389-99. 2011
    ..36, P = 0.007). The identification of >1000 miR genes expressed in different types of ALL forms a comprehensive repository for further functional studies that address the role of miRNAs in the biology of ALL...
  45. doi request reprint NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern
    J D E de Rooij
    Department of Pediatric Hematology Oncology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Leukemia 27:2280-8. 2013
    ..NUP98/JARID1A cases were characterized by HOXA/B gene overexpression, which is a potential druggable pathway. In conclusion, NUP98/JARID1A is a novel recurrent genetic abnormality in pediatric AMKL...
  46. ncbi request reprint Incidence of additional genetic changes in the TEL and AML1 genes in DCOG and COALL-treated t(12;21)-positive pediatric ALL, and their relation with drug sensitivity and clinical outcome
    W A G Stams
    Erasmus MC, Sophia Children s Hospital, Erasmus University Medical Center Rotterdam, Division of Pediatric Oncology Hematology, Rotterdam, The Netherlands
    Leukemia 20:410-6. 2006
    ..78, 95% CI 1.45-23.0; P=0.01) is an independent prognostic factor in DCOG- and COALL-treated t(12;21)-positive ALL...
  47. doi request reprint Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations
    T D Buitenkamp
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Leukemia 26:2204-11. 2012
    ..05; P=0.001). Neither CRLF2 nor JAK2 were predictors for worse prognosis. If confirmed in prospective series, IKZF1 deletions may be used for risk-group stratification in DS ALL...
  48. doi request reprint NKL homeobox genes in leukemia
    I Homminga
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Leukemia 26:572-81. 2012
    ..Identification of a potential common leukemogenic NKL downstream pathway will provide a promising subject for future studies...
  49. doi request reprint MicroRNAs in acute leukemia: from biological players to clinical contributors
    D Schotte
    Department of Pediatric Oncology and Hematology, Erasmus MC Sophia Children s Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Leukemia 26:1-12. 2012
    ..However, emerging knowledge about the biology of miRNAs in leukemia may result into a role for these miRNAs in the diagnosis and treatment of acute leukemia...
  50. ncbi request reprint The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia
    B V Balgobind
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Leukemia 25:1239-48. 2011
    ..To achieve further improvements in outcome, unraveling the biology of MLL-rearranged pediatric AML is warranted...
  51. doi request reprint Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML
    I H I M Hollink
    Department of Pediatric Oncology and Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Leukemia 23:262-70. 2009
    ..However, in NPM1 wild-type CN-AML, FLT3/ITD-positive patients had a significantly worse outcome (pEFS 48 vs 18%; P<0.001). We conclude that NPM1 mutations confer a favorable prognosis in childhood AML and in CN-AML in particular...
  52. ncbi request reprint Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia
    M L den Boer
    Department of Pediatric Oncology and Hematology, Erasmus MC Sophia Children s Hospital, PO Box 2060, 3000 CB Rotterdam, The Netherlands
    J Clin Oncol 21:3262-8. 2003
    ....
  53. doi request reprint Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia
    D Schotte
    Department of Pediatric Oncology and Hematology, Erasmus MC Sophia Children s Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Leukemia 23:313-22. 2009
    ..In conclusion, we identified new miRNA genes and showed that miRNA expression profiles are ALL subtype-specific rather than linked to the differentiation stadium associated with these subtypes...
  54. doi request reprint Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study
    I M Appel
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Erasmus University Medical Center, Rotterdam, The Netherlands
    Leukemia 22:1665-79. 2008
    ..This may be explained by the rapid removal of apoptotic cells from the circulation in vivo. One additional dose of PEG-asparaginase upfront ALL treatment did not lead to other severe toxicities...
  55. pmc Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study
    Brian V Balgobind
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Blood 114:2489-96. 2009
    ..Screening for these translocation partners is needed for accurate treatment stratification at diagnosis...
  56. pmc The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia
    Pieter Van Vlierberghe
    Department of Pediatric Oncology Hematology, Erasmus Medical Center Sophia Children s Hospital, Rotterdam, The Netherlands
    Blood 111:4668-80. 2008
    ..We conclude that SET-NUP214 may contribute to the pathogenesis of T-ALL by enforcing T-cell differentiation arrest...
  57. doi request reprint Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol
    Marieke H van der Linden
    Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Blood 114:3764-8. 2009
    ..This trial was registered at www.clinicaltrials.gov as no. NCT 00015873, and at www.controlled-trials.com as no. ISRCTN24251487...
  58. ncbi request reprint Genomewide identification of prednisolone-responsive genes in acute lymphoblastic leukemia cells
    Wim J E Tissing
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Dr Molewaterplein 60, 3015 GJ Rotterdam, The Netherlands
    Blood 109:3929-35. 2007
    ..Biologic characterization of these genes and pathways might elucidate the action of glucocorticoids in ALL cells, possibly suggesting causes of glucocorticoid resistance and new potential targets for therapy...
  59. ncbi request reprint Resistance to different classes of drugs is associated with impaired apoptosis in childhood acute lymphoblastic leukemia
    Amy Holleman
    Erasmus MC Sophia Children s Hospital, Pediatric Oncology Hematology, Rm Sp2456, Dr Molewaterplein 60, PO Box 2060, 3000 CB Rotterdam, The Netherlands
    Blood 102:4541-6. 2003
    ..This leads to decreased activation of apoptotic parameters in resistant cases of pediatric ALL...
  60. ncbi request reprint Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia
    Ronald W Stam
    Erasmus Medical Center Sophia Children s Hospital, Pediatric Oncology Hematology, Rotterdam, The Netherlands
    Blood 106:2484-90. 2005
    ..Thus, PKC412-induced apoptosis in infant MLL cells is unlikely to be a consequence of FLT3 inhibition alone but may involve inhibition of multiple other kinases by this drug...
  61. doi request reprint Gain of 1q is a marker of poor prognosis in Wilms' tumors
    H Segers
    Department of Pediatric Oncology Hematology, Erasmus MC, Sophia Children s Hospital, Rotterdam, 3015, GJ, The Netherlands
    Genes Chromosomes Cancer 52:1065-74. 2013
    ..Confirmation in other studies is necessary before future therapeutic studies can incorporate 1q gain into new risk stratification schema...
  62. doi request reprint Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia
    B Denys
    Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Leukemia 27:635-41. 2013
    ..In conclusion, 6-color FCM significantly improves MRD analysis in ALL but remains less sensitive than PCR-based MRD-diagnostics...
  63. doi request reprint The hunting of targets: challenge in miRNA research
    F Akbari Moqadam
    Department of Pediatric Oncology and Hematology, Erasmus MC Sophia Children s Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Leukemia 27:16-23. 2013
    ....
  64. doi request reprint Posterior reversible encephalopathy syndrome in childhood cancer
    P de Laat
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, University Medical Center, Rotterdam, The Netherlands
    Ann Oncol 22:472-8. 2011
    ..Posterior reversible encephalopathy syndrome (PRES) is characterized by seizures, headaches, altered mental status, cortical blindness and typical transient lesions on magnetic resonance imaging...
  65. ncbi request reprint L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage
    P C Top
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Pediatr Blood Cancer 44:95-7. 2005
    ..We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts...
  66. ncbi request reprint Molecular determinants of glucocorticoid sensitivity and resistance in acute lymphoblastic leukemia
    W J E Tissing
    University Hospital Rotterdam Sophia Children s Hospital, Department of Paediatric Oncology Hematology, Rotterdam, The Netherlands
    Leukemia 17:17-25. 2003
    ....
  67. ncbi request reprint Ultrafine but not fine particulate matter causes airway inflammation and allergic airway sensitization to co-administered antigen in mice
    C de Haar
    Department of Immunotoxicology, Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands
    Clin Exp Allergy 36:1469-79. 2006
    ..The PM adjuvant activity on allergic sensitization is a possible mechanism of action involved, and the induction of airway inflammation is suggested to be of importance in PM-induced adjuvant activity...
  68. ncbi request reprint L-Asparaginase and the effect of age on coagulation and fibrinolysis in childhood acute lymphoblastic leukemia
    Inge M Appel
    Department of Pediatrics, Div Oncology Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Thromb Haemost 100:330-7. 2008
    ..In conclusion, a more severe decline of anticoagulant and fibrinolytic parameters in children between 11 and 16 years of age underline that these children are at higher risk of thrombosis during ALL induction treatment...
  69. ncbi request reprint Polymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemia
    Robert de Jonge
    Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands
    Blood 113:2284-9. 2009
    ..2-fold increase in ALL risk (P = .001). For the first time, we associate the RFC1 80G>A and NNMT IVS -151C>T variants to an increased ALL susceptibility...
  70. doi request reprint Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia
    Ronald W Stam
    Department of Pediatric Oncology Hematology, Erasmus Medical Center Sophia Children s Hospital, Rotterdam, The Netherlands
    Blood 115:1018-25. 2010
    ....
  71. doi request reprint Various components of the insulin-like growth factor system in tumor tissue, cerebrospinal fluid and peripheral blood of pediatric medulloblastoma and ependymoma patients
    Judith M de Bont
    Department of Pediatric Oncology and Hematology, Erasmus MC University Medical Center, Sophia Children s Hospital, Rotterdam, The Netherlands
    Int J Cancer 123:594-600. 2008
    ..Larger studies should be conducted to validate the predictive values of the levels of intact IGFBP-3 and proteolytic fragments in CSF in the follow-up of medulloblastomas...
  72. pmc MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia
    Diana Schotte
    Erasmus MC Sophia Children s Hospital, Dept of Pediatric Oncology and Hematology, room Sp2456 P O Box 2060, 3000 CB Rotterdam, The Netherlands
    Haematologica 96:703-11. 2011
    ..The aim of the current study was to explore which microRNA are unique for seven different subtypes of pediatric acute lymphoblastic leukemia...
  73. doi request reprint Gene expression profiling-based dissection of MLL translocated and MLL germline acute lymphoblastic leukemia in infants
    Ronald W Stam
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Blood 115:2835-44. 2010
    ..These gene expression profiles should provide important novel insights in the complex biology of MLL-rearranged infant ALL and boost our progress in finding novel therapeutic solutions...
  74. ncbi request reprint Genetic variations in the glucocorticoid receptor gene are not related to glucocorticoid resistance in childhood acute lymphoblastic leukemia
    Wim J E Tissing
    Department of Pediatric Oncology Hematology, Erasmus Medical Center Sophia Children s Hospital, Rotterdam, The Netherlands
    Clin Cancer Res 11:6050-6. 2005
    ..We analyzed whether genetic variations within the GR gene are related to differences in the cellular response to glucocorticoids...
  75. pmc A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study
    Monique L den Boer
    Department of Paediatric Oncology and Haematology, Erasmus MC Sophia Children s Hospital, University Medical Centre, Rotterdam, Netherlands
    Lancet Oncol 10:125-34. 2009
    ..25% of precursor B-ALL cases are genetically unclassified and have intermediate prognosis. We aimed to use a genome-wide study to improve prognostic classification of ALL in children...
  76. ncbi request reprint Inhibin B is superior to FSH as a serum marker for spermatogenesis in men treated for Hodgkin's lymphoma with chemotherapy during childhood
    Robert D van Beek
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Room Sp3435, PO Box 2060, 3000 CB Rotterdam, The Netherlands
    Hum Reprod 22:3215-22. 2007
    ....
  77. ncbi request reprint Increased total-Tau levels in cerebrospinal fluid of pediatric hydrocephalus and brain tumor patients
    Judith M de Bont
    Erasmus MC, University Medical Center, Sophia Children s Hospital, Rotterdam, The Netherlands
    Eur J Paediatr Neurol 12:334-41. 2008
    ..Ongoing studies should determine whether these neurodegenerative markers in CSF can be used to monitor neuronal and axonal degeneration in these patients during therapy and long-term follow up...
  78. ncbi request reprint Decrease in motor performance in children with cancer is independent of the cumulative dose of vincristine
    Annelies Hartman
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, 3000 CB Rotterdam, The Netherlands
    Cancer 106:1395-401. 2006
    ....
  79. ncbi request reprint Changes in hypercoagulability by asparaginase: a randomized study between two asparaginases
    Inge M Appel
    Department of Pediatrics, Division of Oncology Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Blood Coagul Fibrinolysis 17:139-46. 2006
    ..coli L-asparaginase-treated patients only...
  80. pmc Alterations in epithelial and mesenchymal intestinal gene expression during doxorubicin-induced mucositis in mice
    Barbara A E de Koning
    Department of Pediatrics, Divisions of Pediatric Oncology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Dig Dis Sci 52:1814-25. 2007
    ..These data suggest that in response to DOX-induced damage, BMP4 and TCF4 are modulated in such a way that homeostasis of the progenitor compartment is partly preserved...
  81. ncbi request reprint Methotrexate-induced mucositis in mucin 2-deficient mice
    Barbara A E de Koning
    Division of Pediatric Oncology, Laboratory of Pediatrics, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    J Cell Physiol 210:144-52. 2007
    ..A possible explanation is the mechanism by which Muc2 deficiency may trigger the immune system to release interleukin-10, an anti-inflammatory cytokine before MTX-treatment...
  82. ncbi request reprint Impact of two independent bone marrow samples on minimal residual disease monitoring in childhood acute lymphoblastic leukaemia
    Vincent H J van der Velden
    Department of Immunology, Erasmuc MC, Erasmus University Medical Center, The Netherlands
    Br J Haematol 133:382-8. 2006
    ..Nevertheless, MRD-based risk group classification can differ between paired BM samples, mainly because of variation below the quantitative range of the PCR assay rather than to a different distribution of leukaemic cells within the BM...
  83. ncbi request reprint High relapse rate in children with non-advanced nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL or nodular paragranuloma) treated with chemotherapy only
    Martine van Grotel
    Department of Pediatric Oncology Hematology, Erasmus University Medical Center Sophia Children s Hospital, Rotterdam, The Netherlands
    Leuk Lymphoma 47:1504-10. 2006
    ..Moreover, it illustrates that although cure of pediatric NLPHL is feasible with chemotherapy only, high dosages of cytotoxic drugs are necessary as salvage treatment in a relatively high proportion of patients after relapse...
  84. ncbi request reprint High incidence of t(7;12)(q36;p13) in infant AML but not in infant ALL, with a dismal outcome and ectopic expression of HLXB9
    Anne R M von Bergh
    Department of Clinical Genetics, Erasmus MC, Rotterdam, The Netherlands
    Genes Chromosomes Cancer 45:731-9. 2006
    ..The t(7;12) is associated with a poor outcome and an ectopic expression of HLXB9 is commonly involved in this genetic subtype of leukemia...
  85. pmc Expression of the outcome predictor in acute leukemia 1 (OPAL1) gene is not an independent prognostic factor in patients treated according to COALL or St Jude protocols
    Amy Holleman
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Erasmus University Medical Center, Dr Molewaterplein 60, 3015 GJ Rotterdam, The Netherlands
    Blood 108:1984-90. 2006
    ..In conclusion, OPAL1 expression may not be an independent prognostic feature in childhood ALL, and its previously reported prognostic impact appears to be treatment dependent...
  86. ncbi request reprint Microarray-based identification of new targets for specific therapies in pediatric leukemia
    Monique L den Boer
    Erasmus MC Sophia Children s Hospital, Erasmus University Medical Center, Dept of Pediatric Oncology and Hematology, Dr Molewaterplein 60, 3015 GJ Rotterdam, The Netherlands
    Curr Drug Targets 8:761-4. 2007
    ..In this review we will discuss the recent progress that has been made in the use of microarrays for identifying new markers and targets for treatment of acute leukemia in children...
  87. ncbi request reprint Towards targeted therapy for infant acute lymphoblastic leukaemia
    Ronald W Stam
    Department of Paediatric Oncology Haematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Br J Haematol 132:539-51. 2006
    ..Here we review the current acquaintance with the biology of infant ALL and describe how this knowledge may lead to innovative therapeutic approaches...
  88. ncbi request reprint Novel murine B-cell lymphoma/leukemia model to study BCL2-driven oncogenesis
    Jules P P Meijerink
    Department of Pediatrics, Division of Oncology Hematology, Erasmus MC Rotterdam Sophia Children s Hospital, NL 3015GE Rotterdam, The Netherlands
    Int J Cancer 114:917-25. 2005
    ..In conclusion, our mouse model may prove a valuable tool to identify genes that cooperate in BCL2-enforced lymphoma/leukemogenesis...
  89. ncbi request reprint Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia
    Robert de Jonge
    Department of Clinical Chemistry and Pediatric Oncology Hematology, Erasmus MC, Rm L 102, POB 2040, 3000 CA Rotterdam, The Netherlands
    Blood 106:717-20. 2005
    ..SHMT1 1420TT homozygotes only showed decreased MTX sensitivity in the TSI(50, cont). In conclusion, polymorphisms in the folate-related genes MTHFR, MTRR, and SHMT1 are related to MTX resistance in pediatric patients with ALL...
  90. ncbi request reprint The effect of cytostatic drug treatment on intestine-specific transcription factors Cdx2, GATA-4 and HNF-1alpha in mice
    Barbara A E de Koning
    Laboratory of Pediatrics, Division of Pediatric Gastro enterology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Cancer Chemother Pharmacol 57:801-10. 2006
    ....
  91. ncbi request reprint Clustering of hypermethylated genes in neuroblastoma
    Max M van Noesel
    Department of Human Genetics, Academic Medical Center, Amsterdam, The Netherlands
    Genes Chromosomes Cancer 38:226-33. 2003
    ..The methylation pattern therefore supports a model in which CpG islands are not randomly targeted by methylation in cancer. Specific transcriptional silencing probably marks genes that can become methylated...
  92. ncbi request reprint Decrease in peripheral muscle strength and ankle dorsiflexion as long-term side effects of treatment for childhood cancer
    Annelies Hartman
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Pediatr Blood Cancer 50:833-7. 2008
    ....
  93. ncbi request reprint Medical end-of-life decisions for children in the Netherlands
    Astrid M Vrakking
    Department of Public Health, Erasmus MC and Erasmus MC Sophia, Children s Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Arch Pediatr Adolesc Med 159:802-9. 2005
    ..Most end-of-life decision-making studies have, until now, involved either the general population or newborn infants...
  94. pmc Biological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspective
    Judith M de Bont
    Department of Pediatric Oncology and Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Neuro Oncol 10:1040-60. 2008
    ....
  95. doi request reprint Myocyte enhancer factor 2C in hematopoiesis and leukemia
    K Canté-Barrett
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Oncogene 33:403-10. 2014
    ..This review focuses on the role of MEF2C in the hematopoietic system and on aberrant MEF2C expression in human leukemia. ..
  96. ncbi request reprint Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement
    M W J C Jansen
    Department of Immunology, Erasmus MC, Rotterdam, The Netherlands
    Leukemia 21:633-41. 2007
    ..The high frequency of immature and oligoclonal Ig/TCR rearrangements is probably caused by early (prenatal) oncogenic transformation in immature B-lineage progenitor cells with germline Ig/TCR genes combined with a short latency period...
  97. ncbi request reprint The clinical value of follow-up examinations in childhood T-cell acute lymphoblastic leukemia and T-cell non-Hodgkin's lymphoma
    L Huang
    Department of Pediatric Hemato Oncology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Pediatr Blood Cancer 48:468-72. 2007
    ....
  98. ncbi request reprint Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL
    Wendy A G Stams
    Erasmus MC University Medical Center Rotterdam Sophia Children s Hospital, Division of Pediatric Oncology Hematology, Rotterdam, The Netherlands
    Blood 101:2743-7. 2003
    ..Furthermore, we contradict the general thought that leukemic cells specifically lack AS compared with normal bone marrow and blood cells...
  99. ncbi request reprint Glucocorticoid-induced glucocorticoid-receptor expression and promoter usage is not linked to glucocorticoid resistance in childhood ALL
    Wim J E Tissing
    Department of Pediatric Oncology Hematology, Erasmus MC, Sophia Children s Hospital, University Medical Center Rotterdam, Dr Molewaterplein 60, 3015 GJ Rotterdam, The Netherlands
    Blood 108:1045-9. 2006
    ..GC resistance in childhood ALL cannot be attributed to an inability of resistant cells to up-regulate the expression of the GR upon GC exposure, nor to differences in GR promoter usage (at baseline and upon GC exposure)...
  100. ncbi request reprint Contributions of mucosal immune cells to methotrexate-induced mucositis
    Barbara A E de Koning
    Division of Pediatric Oncology, Erasmus MC Sophia Children s Hospital, Dr Molewaterplein 60, PO Box 2060, 3000 GE Rotterdam, The Netherlands
    Int Immunol 18:941-9. 2006
    ..We conclude that mucosal immune responses remain resilient during MTX-induced mucositis. Whereas TNF-alpha production may contribute to mucosal damage, IL-10 may regulate by restricting excessive mucositis...
  101. pmc The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia
    Amy Holleman
    Department of Pediatric Oncology and Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Blood 107:769-76. 2006
    ..051). In conclusion, ALL subtypes have a unique expression pattern of apoptosis genes and our data suggest that selective genes are linked to cellular drug resistance and prognosis in childhood B-lineage ALL...